Randomized Phase 2 trial of Isatuximab during Autologous Stem Cell Collection and transplantation Period in patients with Multiple Myeloma and Lymphoma (Multiple Myeloma)
Sponsor: |
Sanofi Genzyme |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT7444 |
U.S. Govt. ID: |
NCT05346809 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm), Participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each Participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
Investigator
Divaya Bhutani, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with multiple myeloma or lymphoma? |
Yes |
No |
Have you gone through/currently going through stem cell transplant? |
Yes |
No |